Beate Mueller-Tiemann

Beate Mueller-Tiemann

Company: Sanofi

Job title: Vice President - iCMC New Products Program & Pharmaceutics Development Platform


Beate Mueller-Tiemann is currently Head of MSAT for General Medicines and Small Molecules at Sanofi. She is responsible for Sanofi’s product portfolio with an end-to-end responsibility (Drug Substance and Drug Product). Within her scope are various modalities and technologies, most prominently microbial Biotechnology for the production of Biologics as well as classical organic chemistry. Prior to this role Beate was responsible for Sanofi’s Synthetic Molecule CMC Development Platform and CMC Project Management. Beate also lead Technology & Innovation Strategy within Sanofi’s Biologics Platform. 

Previously Beate held the role of Vice President Cell and Protein Sciences within Global Biologics Research at Bayer. In her more than 20 years’ experience in pharmaceutical R&D, she focused on protein science, with various roles in small molecule and biologics drug discovery. She started her career at Sandoz, Basel, Switzerland in Molecular Neurology Research, she moved into Molecular Oncology at Bayer Corporation in West Haven, Connecticut, USA, subsequently joined Schering AG in Berlin, Germany, focusing on High Throughput Technologies in Protein Sciences and Crystallography, before she moved to Bayer’s Research Center in Wuppertal, Germany, establishing and leading the Biologics Research Organization. Beate holds a Ph.D. in Biochemistry, Molecular Biology and Cell Biology from the University of Hamburg, Germany, and a Maîtrise de Biochimie of the University of Montpellier, France. 

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.